First Bank & Trust’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

First Bank & Trust’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-13	Closed	-$2K	–	294
2017 Q2	$2K	Hold	13	–	–	﹤0.01%	237
2017 Q1	$2K	Hold	13	–	–	﹤0.01%	233
2016 Q4	$1K	Buy	+13	New	+$1.37K	﹤0.01%	256

Other funds holding SIOX

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

First Bank & Trust's SIOX Position: Q3 2017 in Review

First Bank & Trust sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2017, closing a stake of 13 shares — an estimated $2K sold.

First Bank & Trust first reported a position in SIOX in Q4 2016 and held it in 3 quarters. The position peaked at $2K in Q2 2017. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

First Bank & Trust reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
First Bank & Trust sold 13 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $2K.
First Bank & Trust first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2016 and held it in 3 quarters.
First Bank & Trust's Sio Gene Therapies Inc. Common Stock position peaked at $2K in Q2 2017.
114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on First Bank & Trust's 13F filing for Q3 2017, filed 25 Oct 2017.